New Patent Issued for Limbrel

May 26, 2009

By Flinn Foundation

[Source: Genetic Engineering News] – Primus Pharmaceuticals, Inc. announces the issuance of a new composition of matter patent for Limbrel, the first prescription medical food product to safely meet the distinctive nutritional requirements of patients with osteoarthritis (OA). U.S. Patent #7,514,469 was recently issued by the U.S. Patent and Trademark Office.

Limbrel contains flavocoxid, a proprietary composition of natural flavonoid ingredients from the plant sources of Scutellaria baicalensis and Acacia catechu that meet the FDA strict safety standard of Generally Recognized As Safe (GRAS). Under this new composition patent, allowable claims for Limbrel include “…improving mobility, range of motion, flexibility and physical function comprising… a mixture of an extract derived from Scutellaria enriched for Free-B-ring flavonoids containing baicalin and an extract derived from Acacia enriched for flavans containing catechin or epicatechin…”

For more information click here.